Posted by Mark Nessim
Reviewed by Dr. Mark, Physician & Formulator
Retatrutide is a triple agonist — it acts on GLP-1, GIP and glucagon receptors at once. Across the TRIUMPH trials reported this summer it produced the largest average weight reductions yet published for a single obesity medication, and one extension arm was still not plateauing at 104 weeks.
It is also investigational: not FDA approved and not available by prescription. Eli Lilly has said it plans to file for approval in the first quarter of 2027, which puts any availability in late 2027 or 2028 at the earliest.
Which is exactly why it is already for sale. Payments to gray-market peptide sellers have climbed for six straight quarters and, per reporting on the market, are on pace to cross a hundred million dollars this year, up from roughly a million a quarter in 2024. The FDA has issued warning letters to vendors offering unapproved semaglutide, tirzepatide and retatrutide. Two of the suppliers named in that reporting had been selling fentanyl and amphetamine precursors before they switched product lines — same contact details, new catalogue.
The part worth being honest about
We are not going to lecture anybody. The trade people are making is a legible one: the real thing is more than a year out, and something wearing its name is available this week.
But the evidence deserves a straight answer. Independent purity testing has collapsed — reporting on the market found per-buyer spending on third-party verification down roughly 88%, even as the number of buyers climbed, with most now relying on certificates supplied by the seller. What testing still happens keeps finding material mislabelled, underdosed, overdosed or contaminated.
And the peptides marketed hardest for fat loss specifically — BPC-157, AOD-9604, CJC-1295 — have no human clinical trial data supporting weight loss. Not thin data. None. We took a longer look at the strongest-hyped of these in our physician's review of what the evidence actually says about BPC-157.
What actually holds up
None of that changes the boring part, which is also the part nobody argues about. Protein intake is the least glamorous lever available and the best established. And creatine has three decades of study behind it, pooled across hundreds of trials, with no greater rate of adverse events than placebo. The strongest findings are for muscle, and increasingly for cognition — a systematic review in Nutrition Reviews this year found accumulating support for memory and processing speed, mostly in combination with training.
It is worth saying where creatine doesn't hold up, too. A recent review asked directly whether its bone benefits were "hope or hype" in older adults, and landed on hype. That is the honest read: the muscle and brain evidence is solid, and the bone marketing has run out ahead of it.
For the avoidance of doubt: ASP-1 does not act on three receptors. It acts on zero receptors. It is a powder that tastes like chocolate, and that is the entire pitch — one scoop of whey isolate, creatine, collagen, L-glutamine, a prebiotic/probiotic complex, magnesium, zinc and methylated B-12, available as a 90-day supply through our HSA/FSA checkout.
"This product is great. I use it everyday mixed with black coffee usually, but have also added Peanut butter, bananas or strawberries. It tastes great."
Dan L. · Verified buyer
The compounds will keep arriving, and some of them will be extraordinary. Protein and creatine will still be here afterwards — unglamorous, well-evidenced, and unlikely to need a warning letter.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
